1065481-28-8 Usage
Uses
Used in Pharmaceutical Industry:
(S)-3-(1-Azidoethyl)-2-chloro-8-fluoroquinoline is used as a potential therapeutic agent for its possible antimicrobial, antimalarial, and antitumor properties. Its structural features allow it to act as an enzyme inhibitor or receptor ligand, making it a promising candidate for the development of new drugs targeting various diseases.
Used in Research and Development:
In the field of research and development, (S)-3-(1-Azidoethyl)-2-chloro-8-fluoroquinoline serves as a reference standard for analytical methods, aiding in the accurate identification and quantification of related compounds. Additionally, it is used as a building block for the synthesis of more complex organic molecules, contributing to the advancement of chemical research and the creation of novel compounds with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1065481-28-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,5,4,8 and 1 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1065481-28:
(9*1)+(8*0)+(7*6)+(6*5)+(5*4)+(4*8)+(3*1)+(2*2)+(1*8)=148
148 % 10 = 8
So 1065481-28-8 is a valid CAS Registry Number.
1065481-28-8Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AND THEIR USES
-
Page/Page column 102-103, (2008/12/04)
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on, or associated with p110 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), non Hodgkins lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.
